Current Report Filing (8-k)
August 16 2017 - 12:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15,
2017
Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)
Texas
|
000-11808
|
59-2219994
|
(State or other jurisdiction of incorporation)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
76102
|
(Address of principal
executive offices)
|
|
Registrant’s telephone number, including area code: (817)
529-2300
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check
mark whether the registrant
is an
emerging growth company as defined in in Rule 405 of
the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective
as of August 15, 2017, Philip J. Rubinfeld, MD, resigned from the
Board of Directors of Wound Management Technologies, Inc. Dr.
Rubinfeld has served on the Board of Wound Management since May of
2010.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Wound Management Technologies, Inc.
|
|
|
|
|
|
Date:
August 16, 2017
|
By:
|
/s/
Michael Carmena
|
|
|
Name:
|
Michael Carmena
|
|
|
Title:
|
Chief Financial
Officer
|
|